Latest AmpliMed Corporation Stories

AmpliMed Corporation, a cancer therapeutics company, announced today that it has entered into a license agreement with leading Korean-based pharmaceutical company Handok Pharmaceuticals for exclusive rights to its investigational cancer therapeutic Amplimexon(R) (imexon for injection) in Korea. Under terms of the agreement, Handok will receive marketing and distribution rights to all cancer indications for Amplimexon in Korea and will pay AmpliMed an up-front fee plus additional payments...